Update on Current and Emerging MS Therapies—Where Do They Act? (Course MS01.17)
Published on February 26, 2009 Expert Dialogue
Published on February 26, 2009 Expert Dialogue
Click here to view our current activities in Neurology.
Dr. Fred Lublin interviews Dr. Robert Lisak regarding the targets of current and emerging MS therapies and their mechanisms of action. In addition, Dr. Lisak explains the rationale behind investigating combinations of existing and developing MS agents based on their mechanisms.
Fred D. Lublin, MD
- Saunders Family Professor of ~Neurology
- The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
- Mount Sinai School of Medicine
- New York, NY
Robert P. Lisak, MD, FAAN, FRCP
- Parker Webber Chair in Neurology Professor and Chair of Neurology
- Professor of Immunology and Microbiology
- Wayne State University School of Medicine
- Detroit, MI
Robert P. Lisak, MD, FAAN, FRCP, has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Anne H. Cross, MD, has received grant/research support from Acorda Therapeutics, and Genentech, Inc; is on the speakers bureau for Bayer Healthcare and Teva Neuroscience; and is on the advisory boards of Bayer Healthcare, Biogen Idec, and BioMS Medical.
Tracy M. DeAngelis, MD, is on the speakers bureau for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD, has received grant/research support and has received honoraria from Bayer and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience.
Matilde Inglese, MD, PhD, is on the speakers bureau for and the advisory board of Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP, has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD, has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Clyde E. Markowitz, MD, Clyde E. Markowitz, MD, has received honoraria from Bayer, Biogen Idec, and Teva Neuroscience; is a consultant for Bayer, Genentech Inc, Biogen Idec, BioMS Medical, Eli Lilly and Company, EMD Serono, Novartis Pharmaceuticals Corporation and Teva Neuroscience.
Aaron E. Miller, MD, has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Available for CME/CE:
Physicians
Publish Date: Feb 26, 2009 Termination Date: Feb 26, 2010Nurses
Publish Date: Feb 26, 2009 Termination Date: Feb 26, 2010Pharmacists
Publish Date: Feb 26, 2009 Termination Date: Feb 26, 2010Estimated time for completion of this activity:
CPE: 1.0 hour
Target Audience
This activity is designed for neurologists and other clinicians who specialize in and care for patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with multiple sclerosis.
Learning Objective (s)
- Assess treatment strategies with regard to MOA utilizing current therapies in MS patients that reduce disease progression.
- Evaluate potential treatment strategies with regard to MOA utilizing emerging therapies as they become available in MS patients that reduce disease progression.
- Assess potential treatment strategies with regard to MOA combining current and emerging therapies as they become available in MS patients that reduce disease progression.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This expert dialogue is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-09-13-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Lauren A. Cerruto has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Bruce A. C. Cree, MD, PhD, MCR has received grant/research support from BioMS Medical, EMD Serono, and Genentech, Inc; is a consultant for Biogen Idec and BioMS Medical; and is on the speakers bureau for Biogen Idec and Teva Neuroscience.
Anne H. Cross, MD has received grant/research support from Acorda Therapeutics, and Genentech, Inc; is on the speakers bureau for Bayer Healthcare and Teva Neuroscience; and is on the advisory boards of Bayer Healthcare, Biogen Idec, and BioMS Medical.
Tracy M. DeAngelis, MD is on the speakers bureau for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD has received grant/research support and has received honoraria from Bayer and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience.
Matilde Inglese, MD, PhD is on the speakers bureau for and the advisory board of Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Clyde E. Markowitz, MD Clyde E. Markowitz, MD, has received honoraria from Bayer, Biogen Idec, and Teva Neuroscience; is a consultant for Bayer, Genentech Inc, Biogen Idec, BioMS Medical, Eli Lilly and Company, EMD Serono, Novartis Pharmaceuticals Corporation and Teva Neuroscience.
Aaron E. Miller, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Genentech, Inc
Novartis Pharmaceuticals Corporation
Teva Neuroscience
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Feb 26, 2009 Termination Date: Feb 26, 2010Nurses
Publish Date: Feb 26, 2009 Termination Date: Feb 26, 2010Pharmacists
Publish Date: Feb 26, 2009 Termination Date: Feb 26, 2010Estimated time for completion of this activity:
CPE: 1.0 hour
Target Audience
This activity is designed for neurologists and other clinicians who specialize in and care for patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for treating and managing patients with multiple sclerosis.
Learning Objective (s)
- Assess treatment strategies with regard to MOA utilizing current therapies in MS patients that reduce disease progression.
- Evaluate potential treatment strategies with regard to MOA utilizing emerging therapies as they become available in MS patients that reduce disease progression.
- Assess potential treatment strategies with regard to MOA combining current and emerging therapies as they become available in MS patients that reduce disease progression.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This expert dialogue is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-09-13-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Lauren A. Cerruto has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Bruce A. C. Cree, MD, PhD, MCR has received grant/research support from BioMS Medical, EMD Serono, and Genentech, Inc; is a consultant for Biogen Idec and BioMS Medical; and is on the speakers bureau for Biogen Idec and Teva Neuroscience.
Anne H. Cross, MD has received grant/research support from Acorda Therapeutics, and Genentech, Inc; is on the speakers bureau for Bayer Healthcare and Teva Neuroscience; and is on the advisory boards of Bayer Healthcare, Biogen Idec, and BioMS Medical.
Tracy M. DeAngelis, MD is on the speakers bureau for Bayer and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD has received grant/research support and has received honoraria from Bayer and Teva Neuroscience; is a consultant for EMD Serono and Teva Neuroscience.
Matilde Inglese, MD, PhD is on the speakers bureau for and the advisory board of Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received grant/research support from Biogen Idec, BioMS Medical, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Biogen Idec, Genentech, Inc, MediciNova and Teva Neuroscience; is on the speakers bureau for Bayer and Teva Neuroscience; and is on the advisory boards of Bayer, Biogen Idec, Genentech, Inc, MediciNova, and Teva Neuroscience.
Fred D. Lublin, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Teva Neuroscience; is a consultant for Actelion, Bayer, Biogen Idec, BioMS Medical, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech, Inc, Genmab, LifeCycle Pharma, Medarex, MediciNova, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Teva Neuroscience; is on the speakers bureau for Bayer, EMD Serono, Pfizer Inc, and Teva Neuroscience; and owns stock in Cognition Therapeutics.
Clyde E. Markowitz, MD Clyde E. Markowitz, MD, has received honoraria from Bayer, Biogen Idec, and Teva Neuroscience; is a consultant for Bayer, Genentech Inc, Biogen Idec, BioMS Medical, Eli Lilly and Company, EMD Serono, Novartis Pharmaceuticals Corporation and Teva Neuroscience.
Aaron E. Miller, MD has received grant/research support from Acorda Therapeutics, Biogen Idec, Genzyme, Novartis Pharmaceuticals Corporation, Teva Neuroscience; is a consultant for Acorda Therapeutics, Bayer, Biogen Idec, EMD Serono, Genentech, Inc, GlaxoSmithKline, Sanofi-Aventis, and Teva Neuroscience and is on the speakers bureau for Bayer, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Genentech, Inc
Novartis Pharmaceuticals Corporation
Teva Neuroscience
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



